Laurion Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Laurion Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-450,118	Closed	-$24.3M	–	1979
2017 Q3	$24.3M	Buy	450,118 +397,618	+757%	+$23.3M	0.11%	158
2017 Q2	$2.95M	Buy	+52,500	New	+$2.1M	0.02%	684
2015 Q3	–	Sell	-108,000	Closed	-$4.92M	–	990
2015 Q2	$4.92M	Buy	+108,000	New	+$4.34M	0.05%	299
2014 Q1	–	Sell	-76,100	Closed	-$1.96M	–	329
2013 Q4	$1.96M	Buy	+76,100	New	+$1.85M	0.07%	115

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Laurion Capital Management's PTLA Position: Q4 2017 in Review

Laurion Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2017, closing a stake of 450,118 shares — an estimated $24.3M sold.

Laurion Capital Management first reported a position in PTLA in Q4 2013 and held it in 4 quarters. The position peaked at $24.3M in Q3 2017. 215 funds tracked by Wall St. Rank hold PTLA as of Q4 2017.

Laurion Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Laurion Capital Management sold 450,118 Portola Pharmaceuticals, Inc. shares in Q4 2017, an estimated $24.3M.
Laurion Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2013 and held it in 4 quarters.
Laurion Capital Management's Portola Pharmaceuticals, Inc. position peaked at $24.3M in Q3 2017.
215 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2017.

Based on Laurion Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.